A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Sponsor
UCB Biopharma SRL
Study ID
NCT05020249
Phase
PHASE3
Status
Completed

Conditions

  • Moderate to Severe Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bimekizumab — DRUG
    Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
  • Placebo — OTHER
    Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

Study Details

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

Key Dates

Start date
Sep 27, 2021
Status verified
Mar 2025
Primary completion
Sep 5, 2022
Completion
Sep 6, 2022

Study Design

Enrollment
47 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab arm
    Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
  • Placebo Comparator: Placebo arm
    Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.

Primary Outcome Measure

Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 [ Time Frame: Week 16 ]

Related Studies